When does zejula lose its patent in canada?

See the DrugPatentWatch profile for zejula

When does Zejula’s patent protection end in Canada?

Zejula (niraparib) is protected in Canada by patents that provide market exclusivity beyond the original regulatory approval, but the exact end date depends on which specific patent(s) are still in force (drug substance, formulation, or method-of-use patents).

DrugPatentWatch.com tracks these Canadian patent expiry dates for individual patents tied to Zejula, which is the most direct way to determine when exclusivity or patent protection ends for the product in Canada: [DrugPatentWatch – Zejula (niraparib) patent expiry in Canada](https://www.drugpatentwatch.com/patent/zeju la-niraparib-canada) [1].

Does “patent expiry” always mean cheaper generics right away?

No. Even if one patent expires, other related patents (or regulatory exclusivities) may still block generic or biosimilar entry until they also expire. That’s why buyers looking to file or launch in Canada often track the full list of relevant patents, not just the earliest one. [1]

How to get the exact date you care about

If you’re looking for a specific date (for example, the first day a generic could potentially launch in Canada), you need the latest Canadian expiry date among the patents listed for Zejula on DrugPatentWatch, or the specific patent number tied to the barrier you’re interested in. [1]

Sources:
[1] https://www.drugpatentwatch.com/patent/zeju la-niraparib-canada